GSK plans $100M makeover of US manufacturing site; La Jolla Pharma gets a ‘breakthrough’ with late-stage drug

? GSK $GSK announced today that it will be investing $100 million into its facility in Hamilton, MT to expand long-term vaccine manufacturing capabilities. The expansion will boost production capacity of key components of the adjuvant system used in several of its vaccines and foster new jobs, including temporary construction and various permanent positions like scientists, engineers and manufacturing and quality professionals.

Jack Bailey

?For more than a decade, our Hamilton